Background: Augmentation of Ca2+ entry via transient receptor potential canonical channel 6 (TRPC6) in response to stimulation of endothelin type A receptor (ETAR) with endothelin-1 is involved in the development of pulmonary arterial hypertension (PAH). For the drug therapy against PAH, Gs protein-coupled prostaglandin I2 receptor agonists to activate adenylate cyclase (AC)-cAMP-protein kinase A (PKA) signaling pathway are administered. This study examined the role of AC-cAMP-PKA pathway in regulation of receptor-operated Ca2+ entry (ROCE) via ETAR-activated TRPC6.
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Methods: In HEK293 cells coexpressing ETAR and TRPC6, intracellular free Ca2+ concentration was monitored by using a fluorescent Ca2+ indicator, fura-2/AM. To identify the target site(s) of TRPC6 for phosphorylation by PKA, serine residues at positions 14, 28, and 321, and threonine at 69 were replaced with alanine.
Results: Stimulation of ETAR induced ROCE in TRPC6-expressing HEK293 cells where store-operated Ca2+ channels had been maximally activated by thapsigargin-induced Ca2+-depletion/Ca2+-restoration. The ROCE was inhibited by forskolin and papaverine to activate cAMP-PKA pathway, while it was potentiated by Rp-8-BrcAMP, a PKA inhibitor. Inhibitory effects of forskolin and papaverine were partially cancelled by replacing Ser28 but not Thr69 of TRPC6 with alanine. Immunoblotting with Phos-tag biotin to detect phosphorylated proteins demonstrated that wild-type and mutant TRPC6 proteins were phosphorylated under basal condition. In vitro kinase assay with TRPC6 proteins dephosphorylated with a phosphatase pretreatment revealed that PKA can phosphorylate TRPC6 on Ser28 and Thr69.
Conclusions: ROCE via ETAR-activated TRPC6 is negatively regulated by PKA-mediated phosphorylation of TRPC6 at Ser28 but not at Thr69 in vivo, although PKA can phosphorylate TRPC6 on Ser28 and Thr69 in vitro. A growing body of evidence suggests that microRNAs (miRNAs) regulate endothelin-1 (Edn1) mRNA bioavailability (Jacobs et. al.,2013) . miRNAs are a family of small (18-24 nt), single stranded, noncoding RNAs that are components of the RNA-induced Silencing Complex (RISC). RISC controls gene expression by blocking protein translation or inducing degradation of target mRNAs by binding to the 3′ untranslated region (UTR). In humans and other mammals, the Edn1 3′ UTR represents over 50% of the total mRNA length and contains long tracts of highly conserved sequence. Alignment of 19 species of class Mammalia yielded greater than 80% sequence identity between any two Edn1 3′UTRs. The level of conservation by itself suggests that there are elements in the 3′ UTR that are critical for tight regulation of Edn1 mRNA availability. In silico examination of the murine Edn1 3′ UTR revealed two likely miR-709 binding sites at positions 610 and 668 (microRNA.org). mFold (http://mfold.rna.albany.edu) was used to examine the free energy of 70 nucleotides flanking the putative miRNA binding sites in the Edn1 3′UTR. The minimum free energy values were higher than randomly expected (delta G = − 13.4 kcal/mol) (Martin et al., 2007) , suggesting that these sites are accessible to miRNA-RISC complexes. We have discovered that ET-1 mediated constrictor responses in human coronary artery (CA) in vitro are not attenuated in atherosclerotic compared to histologically normal arteries, despite extensive thinning of the medial smooth muscle layer with disease. This observation can be replicated in the aorta of mice in which 50% of smooth muscle cells are ablated without subsequent loss of ET-1 response. To further understand these data we have investigated the effect of altered arterial structure (medial thinning, intimal proliferation and calcium/lipid deposition) on the passive mechanical properties of the vessel wall and determined whether this may contribute to the maintained ET-1 response in diseased CA. Passive force-stretch tests were performed to characterize the artery mechanical response and tangent stiffness at physiological pressure of normal and diseased CA rings. Results demonstrated that differences in material and geometry lead to a significant increase in the passive response with disease. However when these structural differences were included in a finite element analysis to predict the effect of plaque morphology, material properties and muscle contractile strain on both the passive and ET-mediated active responses, it was found that the comparable ET-1 responses could only be explained by assigning similar active forces in both the normal and diseased CA rings. This study has identified an appropriate methodology to correlate pharmacological and biomechanical models of stress and strain in arteries. However, although the atherosclerotic CA wall exhibits structural remodeling resulting in arterial stiffening this does not account for the ability of the diseased arteries to contract to ET-1 to the same extent as normal arteries.
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